Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2003

View Archived Issues

Schwarz updates pipeline development

Regeneron summarizes financial and development results for the first quarter

Human Genome Sciences updates plans for advancing pipeline

Combined use of two drug delivery systems after cataract surgery

Low-dose nitroglycerin delays biochemical failure after radical prostatectomy

Adherex enters screening agreement with NCI

Good oral absorption reported in humans for RSD-1235

Anti-VEGF antibody fragment safe, improves visual acuity in neovascular AMD

New data on the efficacy and safety of verteporfin phototherapy in macular degeneration

Several series of p38 MAP kinase inhibitors presented by GSK

Novel MMP-13 inhibitors claimed in recent patent literature

Antitumor platinum complex prepared and tested by Spanish researchers

Celltech R&D designs new p38 kinase inhibitors

Sanofi-Synthelabo claims new TNF-alpha production inhibitors for pain, inflammation, etc.

Boehringer Ingelheim reports novel Abeta modulators for AD and other uses

Telik reveals R&D highlights during the first quarter

Ongoing discovery and development efforts at Actelion

Phase I Davanat trial begins patient dosing

Panacea establishes Proteus diagnostics subsidiary

Launch of Klonopin Wafers

British Biotech and MerLion to develop antibacterial ribosome inhibitors

ISIS-113715 evaluated in new phase I trial for type 2 diabetes

TheraCLEC study for malabsorption completed

AVI BioPharma seeks orphan drug status for AVI-4020

Trial planned for RG-1068 in patients with schizophrenia

Wilex licenses antibody from VU University Medical Center Amsterdam

New data on the pharmacokinetics, efficacy and safety of dalbavancin

Ramoplanin is more effective than vancomycin or metronidazole in hamsters with CDAD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...